Hartig Seeks $3M In Attys' Fees In Product-Hopping Suit

Law360 (September 25, 2018, 9:46 PM EDT) -- The Hartig Drug Co. Inc. has asked a Delaware federal judge to award it $3 million in attorneys' fees in a suit against Allergan Inc., Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd. alleging product-hopping over eye care products Zymar and Zymaxid.

Hartig on Tuesday filed the motion for attorneys' fees – along with litigation expense reimbursement and an incentive payment to the company – a move that came months after the defendant companies said in February that they had agreed to pay $9 million to settle the suit. U.S. District Judge Joseph F. Bataillon later signed off on a bid...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!